Biote Corp. operates a practice-building business within the hormone optimization space, providing a comprehensive platform for certified practitioners to establish and manage hormone replacement therapy (HRT) programs. The company offers the Biote Method, which includes education, training, and certification for clinicians, alongside proprietary clinical decision support software, inventory management tools, and digital marketing support. Biote generates revenue by charging partnered clinics fees for these services and through the sale of a private-labeled line of dietary supplements designed to address hormone and vitamin deficiencies. The platform supports practitioners treating menopause, andropause, and hypogonadism, utilizing FDA-registered outsourcing facilities for the supply of HRT products such as creams, gels, patches, pills, injections, and compounded bioidentical hormone pellets. The company serves a network of certified practitioners and their patient populations, focusing on personalized hormone optimization solutions.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Healthcare Plans Homepage biote.com
Sector Healthcare IR page ir.biote.com
Tags
hormone replacement therapy, practice building, clinical decision support, inventory management, dietary supplements, bioidentical hormones, menopause treatment, andropause treatment, practitioner certification, medical education, Biote Method, Biote-branded dietary supplements
Press page —

Metrics

Valuation  
Market cap $ 33.173M
Market cap (USD) $ 33.173M
P/E -11.00
PEG —
P/BV -0.51
P/S 0.19
P/OCF 2.37
P/FCF 4.48
Dividend yield 35.5%
Turnover / mcap —
Returns  
ROE -46.2%
ROI 62.2%
ROIC 68.7%
Profit margin 14.1%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Revenue 192.219M 197.191M 185.36M 164.957M 0
Net profit 27.045M 3.157M 3.316M -969K 0
Free cash flow 30.179M 38.813M 26.524M -9.49M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Share price 2.6 6.18 4.94 3.73 —
Price performance 12m -0.58 0.25 0.32 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 5.23M 6.95M 6.81M 7.63M 6.87M
↳ YoY growth +32.8% -2.0% +12.1% -10.0%
Borrowings, current (USD) — 5M 6.25M 6.25M 6.25M 6.25M
Borrowings, non-current (USD) — 32M 112M 107M 101M 95.8M
Lease liabilities (USD) — 375,000 2.09M 1.99M 3.41M 2.89M
Cash and deposits (USD) 1,594 130,359 79.2M 89M 39.3M 24.1M
Intangible assets (USD) — — — 0.00 5.5M 4.27M
Right-of-use assets (USD) — 356,000 2.05M 1.88M 3.25M 2.7M
Net debt (borrowings + leases - cash) (USD) — — 41.2M 25.9M 71.5M 80.8M
Cash flow detail
Operating cash flow (USD) — -1.37M -9.16M 26.9M 45.2M 35.2M
Purchases of property, plant and equipment (USD) — -1.45M -333,000 -359,000 -6.43M -5.02M
Purchases of intangible assets (USD) — -2.36M -1.51M -2.35M -526,000 -1.85M
Change in receivables (cash effect) (USD) — -752,000 -1.56M -505,000 -2.27M -958,000
Change in inventories (cash effect) (USD) — -5.76M -1.71M -6.1M 3.71M -6.24M
Change in payables (cash effect) (USD) — 281,304 416,000 -165,000 1.55M 1.01M
Dividends paid (cash effect) (USD) — -11.4M -12.9M -8.69M -4.74M -1.73M
Share buybacks (cash effect) (USD) — — — — -5.6M -3.37M
Interest paid (cash effect) (USD) — -1.46M -4.43M -9.48M -9.54M -7.88M
Income taxes paid (cash effect) (USD) — -171,000 -282,000 -4.43M -2.59M -2.75M
Share-based compensation (USD) — — 82.2M 9.06M 8.74M 8.92M
Operating cash flow before change in receivables (USD) — 34.5M -7.6M 27.4M 47.5M 36.2M
Free cash flow (OCF - PPE - intangibles) (USD) — 29.9M -11M 24.2M 38.3M 28.3M
Income detail
Total comprehensive income (USD) — -17,000 1.32M 19,000 -22,000 31.6M
Comprehensive income to owners (USD) — 32.6M 1.32M -2.8M 31,000 31.6M
Provision for credit losses (USD) — 240,000 -155,000 663,000 1.49M 1.72M
Credit cost ratio (credit losses / average receivables) (%) — — 2.5% 9.6% 20.6% 23.7%
Reported May 20, 2021 Mar 29, 2023 Aug 11, 2023 May 10, 2024 Mar 14, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Biote Reports Third Quarter 2026 Financial Results Bull 0 Bear 5 Results

Company maintains 2026 financial outlook

Third Quarter 2026 Financial Summary

•Revenue of $43.3 million

•Gross profit margin of 67.7%

•Net income of $0.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.01

•Adjusted EBITDA1 of $5.1 million and Adjusted EBITDA margin1 of 11.7%

IRVING, TX–(BUSINESS WIRE)–November 4, 2026–Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the third quarter ended September 30, 2026.

“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated,” said Bob Peterson, Biote’s interim Chief Executive Officer. “Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”

Mr. Peterson continued, “As part of this increased engagement, our Chief Medical Officer, Dr.

October 21, 2026

PDF Version

IRVING, Texas--(BUSINESS WIRE)--Oct. 21, 2026-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners’ patients, today announced the Company will provide third quarter financial results on Wednesday, November 4, 2026, after the close of the market. A conference call to discuss the firm’s results will be held at 5:00 p.m. ET the same day.

Conference Call Details

The conference call may be accessed by dialing (844) 481-2820(U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here, shortly after the event concludes.

About Biote

Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our ability and the ability of certain third parties to effectively support the manufacturing of bio-identical hormones for prescribers, including the impact of the voluntary product recall of certain hormone pellets and our continued reliance on third-party pellet suppliers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; our ability to achieve previously announced financial guidance or the possibility that we may need to further revise such guidance; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricanes and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, as supplements by Biote’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021664443/en/

Investor Relations: Eric Prouty AdvisIRy Partners [email protected]

Media: [email protected]

Source: biote Corp.

Biote Reports Second Quarter 2026 Financial Results Bull 0 Bear 4 Results

August 5, 2026

PDF Version

Continued progress in advancing strategic initiatives

Updates full-year outlook

Second Quarter 2026 Financial Highlights

  • Revenue of $44.2 million

  • Gross profit margin of 65.4%

  • Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the second quarter of 2025

  • Adjusted EBITDA1 of $5.6 million and Adjusted EBITDA margin1 of 12.6%

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the second quarter ended June 30, 2026.

“Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterson, Biote’s interim Chief Executive Officer. “While not yet evident in our financial results, these foundational improvements have strengthened the core of our business and enhanced our resiliency, which we expect will drive improved financial performance in the second half.”

Mr. Peterson continued, “Our second quarter results primarily reflect continued impacts from the voluntary product recall, which affected revenue and margin. Underpinned by our leadership position and continued innovation, we remain focused on driving growth.”

2026 Second Quarter Financial Review

(All financial result comparisons made are against the prior-year period unless otherwise noted)

Total revenue was $44.2 million, a decrease of 9.5% from $48.9 million. Procedure revenue declined 13.9% to $30.3 million, and was impacted by the voluntary recall initiated in January 2026 of certain hormone pellets shipped by Asteria Health. Dietary supplements revenue grew 5.7% to $11.4 million.

Gross profit margin was 65.4%, as compared to 71.6%, as a result of impacts from the voluntary recall, which included the sourcing of replacement products from our third-party pellet suppliers at higher costs and reduced manufacturing efficiencies at Asteria Health.

| _____________________________ |

| 1Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. Please see “Discussion of non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measure. |

Operating income (loss) declined to a loss of $(3.5) million, from income of $10.8 million. Operating income (loss) decreased due to lower revenue and gross profit, as well as higher operating expenses.

Net loss was $(7.4) million and diluted loss per share attributable to biote Corp. stockholders was $(0.23), as compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10. Net income (loss) included a loss of $(0.8) million and $(1.8) million for the second quarter of 2026 and 2025, respectively, due to changes in the fair value of the earnout liabilities.

Adjusted EBITDA of $5.6 million decreased from $15.2 million and Adjusted EBITDA margin decreased to 12.6% from 31.1%. Both Adjusted EBITDA and Adjusted EBITDA margin decreased due to lower revenue, reduced gross profit and higher operating expenses.

Summary and 2026 Financial Outlook

Mr. Peterson concluded, “Our strategic initiatives program continues to guide the Company, and we are confident the foundational work completed over the past year has strengthened our business. As we enter the second half of 2026, we are moving into the next phase of our strategic roadmap, which is designed to drive deeper operational improvements that restore growth and improve the consistency of our financial performance. Key areas of focus include enhancing the practitioner experience; accelerating sales productivity; and driving growth across our network.

In terms of our 2026 outlook, we expect procedure revenue to show sequential improvement in both the third and fourth quarters, benefiting from a return to normalized inventory levels at Asteria Health. However, the impacts from the voluntary product recall earlier in the year have delayed our expected return to year-over-year procedure revenue growth. As a result, we are revising our full‑year financial outlook to reflect our first half performance and our current expectations for the remainder of the year. We remain focused on executing our strategy with discipline and continuing to advance the long‑term fundamentals of the business.”

| ($ in millions) | 2026 Guidance |

| Revenue | Above $175 million |

| Adjusted EBITDA2 | Above $25 million |

  • Procedure revenue is expected to improve sequentially in both the third and fourth quarters, versus prior guidance that anticipated a return to year-over-year growth in the second half. However, year-over-year procedure revenue in these periods is still expected to be negative due to the first-half disruption of the voluntary recall affecting near-term performance.

  • 2026 Dietary supplements revenue is expected to grow at a mid to high single digit rate from 2025, unchanged from prior guidance.

| _____________________________ |

| 2 Please see “Forward-Looking Non-GAAP Financial Measures" below for additional information about forward-looking Adjusted EBITDA. |

Conference Call:

Biote management will host a conference call to review these results and provide a business update beginning at 5:00 p.m. ET on Wednesday, August 5, 2026. To access the conference call by telephone, please dial (646) 307-1963 (U.S toll-free) or (800) 715-9871 (International) and reference conference ID: 1792102. To access a live webcast of the call, interested parties may use the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.

Discussion of Non-GAAP Financial Measures

To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a non-GAAP financial measure that it calculates as net income (loss) before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal settlements, inventory fair value write-up, transaction-related expenses, restructuring-related expenses, certain other expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure.

We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management.

Adjusted EBITDA and Adjusted EBITDA margin have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:

  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA and Adjusted EBITDA margin do not reflect cash capital expenditure requirements for such replacements of our assets;

  • Adjusted EBITDA and Adjusted EBITDA margin do not reflect changes in, or cash requirements for, our working capital needs; and

  • Adjusted EBITDA and Adjusted EBITDA margin do not reflect tax payments that may represent a reduction in cash available to us.

In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the exercise of judgment by Biote’s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin alongside other financial performance measures, including net income (loss) and our other GAAP results.

Forward-Looking Non-GAAP Financial Measures

The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company’s projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss) for the periods presented will consist of items similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal expenses. The timing and amount of any of these excluded items could significantly impact the Company’s GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.

About Biote

Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “outlook,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our ability and the ability of certain third parties to effectively support the manufacturing of bio-identical hormones for prescribers; including the impact of the voluntary product recall of certain hormone pellets and our continued reliance on third-party pellet suppliers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; our ability to achieve the financial guidance provided in this press release or the possibility that we may need to further revise such guidance; and the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, as supplemented by Biote's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

Financial Tables

| | | | | | | |

| Biote Corp. |

| Condensed Consolidated Balance Sheets (In Thousands) (Unaudited) |

| | | | | | | |

| | | June 30, | | | December 31, | |

| | | 2026 | | | 2025 | |

| Assets | | | | | | |

| Current assets: | | | | | | |

| Cash and cash equivalents | | $ | 11,168 | | | $ | 24,123 | |

| Accounts receivable, net | | | 7,810 | | | | 6,868 | |

| Inventory, net | | | 18,331 | | | | 19,064 | |

| Other current assets | | | 5,731 | | | | 4,615 | |

| Total current assets | | | 43,040 | | | | 54,670 | |

| Property and equipment, net | | | 12,847 | | | | 10,753 | |

| Capitalized software, net | | | 4,897 | | | | 4,525 | |

| Goodwill | | | 5,833 | | | | 5,833 | |

| Intangible assets, net | | | 3,649 | | | | 4,266 | |

| Operating lease right-of-use assets | | | 6,846 | | | | 2,701 | |

| Deferred tax assets, net | | | 24,515 | | | | 24,793 | |

| Other non-current assets | | | 72 | | | | 72 | |

| Total assets | | $ | 101,699 | | | $ | 107,613 | |

| | | | | | | |

| Liabilities and Stockholders’ Deficit | | | | | | |

| Current liabilities: | | | | | | |

| Accounts payable | | $ | 6,576 | | | $ | 6,826 | |

| Accrued expenses | | | 14,321 | | | | 9,806 | |

| Term loan, current | | | 3,125 | | | | 6,250 | |

| Deferred revenue, current | | | 2,623 | | | | 3,017 | |

| Earnout liabilities, current | | | 2,750 | | | | — | |

| Operating lease liabilities, current | | | 705 | | | | 592 | |

| Share repurchase liabilities | | | — | | | | 18,500 | |

| Total current liabilities | | | 30,100 | | | | 44,991 | |

| Term loan, net of current portion | | | 118,377 | | | | 95,782 | |

| Revolving loans | | | — | | | | 5,000 | |

| Deferred revenue, net of current portion | | | 791 | | | | 1,097 | |

| Operating lease liabilities, net of current portion | | | 6,433 | | | | 2,298 | |

| Other non-current liability | | | — | | | | 344 | |

| TRA liability | | | 4,190 | | | | 4,386 | |

| Earnout liabilities | | | — | | | | 4,112 | |

| Total liabilities | | | 159,891 | | | | 158,010 | |

| Commitments and contingencies | | | | | | |

| Stockholders’ Deficit | | | | | | |

| Preferred stock | | | — | | | | — | |

| Class A common stock | | | 3 | | | | 3 | |

| Class V voting stock | | | 1 | | | | 1 | |

| Additional paid-in capital | | | — | | | | — | |

| Accumulated deficit | | | (50,941 | ) | | | (49,549 | ) |

| Accumulated other comprehensive loss | | | (25 | ) | | | (29 | ) |

| Treasury stock, at cost | | | (14,828 | ) | | | (8,965 | ) |

| biote Corp.’s stockholders’ deficit | | | (65,790 | ) | | | (58,539 | ) |

| Noncontrolling interest | | | 7,598 | | | | 8,142 | |

| Total stockholders’ deficit | | | (58,192 | ) | | | (50,397 | ) |

| Total liabilities and stockholders’ deficit | | $ | 101,699 | | | $ | 107,613 | |

| | | | | | | |

| Biote Corp. |

| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In Thousands, except share and per share amounts) (Unaudited) |

| | | | | | | |

| | | Three Months Ended June 30, | | | Six Months Ended June 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Revenue: | | | | | | | | | | | | |

| Product revenue | | $ | 43,381 | | | $ | 47,657 | | | $ | 87,276 | | | $ | 94,682 | |

| Service revenue | | | 851 | | | | 1,206 | | | | 1,891 | | | | 3,173 | |

| Total revenue | | | 44,232 | | | | 48,863 | | | | 89,167 | | | | 97,855 | |

| Cost of revenue | | | | | | | | | | | | |

| Cost of products | | | 14,301 | | | | 12,811 | | | | 27,046 | | | | 24,465 | |

| Cost of services | | | 1,013 | | | | 1,064 | | | | 2,250 | | | | 2,020 | |

| Cost of revenue | | | 15,314 | | | | 13,875 | | | | 29,296 | | | | 26,485 | |

| Selling, general and administrative | | | 32,426 | | | | 24,223 | | | | 60,213 | | | | 50,915 | |

| Income (loss) from operations | | | (3,508 | ) | | | 10,765 | | | | (342 | ) | | | 20,455 | |

| Other income (expense), net: | | | | | | | | | | | | |

| Interest expense, net | | | (2,183 | ) | | | (2,852 | ) | | | (4,155 | ) | | | (5,757 | ) |

| Loss on extinguishment of debt | | | (648 | ) | | | — | | | | (648 | ) | | | — | |

| Gain (loss) from change in fair value of earnout liabilities | | | (787 | ) | | | (1,832 | ) | | | 1,362 | | | | 8,856 | |

| Other income (expense), net | | | (6 | ) | | | (6 | ) | | | (11 | ) | | | (24 | ) |

| Total other income (expense), net | | | (3,624 | ) | | | (4,690 | ) | | | (3,452 | ) | | | 3,075 | |

| Income (loss) before provision for income taxes | | | (7,132 | ) | | | 6,075 | | | | (3,794 | ) | | | 23,530 | |

| Income tax expense | | | 296 | | | | 2,150 | | | | 958 | | | | 3,766 | |

| Net income (loss) | | | (7,428 | ) | | | 3,925 | | | | (4,752 | ) | | | 19,764 | |

| Less: Net income (loss) attributable to noncontrolling interest | | | (865 | ) | | | 740 | | | | (466 | ) | | | 2,861 | |

| Net income (loss) attributable to biote Corp. stockholders | | $ | (6,563 | ) | | $ | 3,185 | | | $ | (4,286 | ) | | $ | 16,903 | |

| | | | | | | | | | | | | |

| Other comprehensive income: | | | | | | | | | | | | |

| Foreign currency translation adjustments | | | 2 | | | | 9 | | | | 4 | | | | 5 | |

| Other comprehensive income | | | 2 | | | | 9 | | | | 4 | | | | 5 | |

| Comprehensive income (loss) | | $ | (7,426 | ) | | $ | 3,934 | | | $ | (4,748 | ) | | $ | 19,769 | |

| | | | | | | | | | | | | |

| Net income (loss) per common share | | | | | | | | | | | | |

| Basic | | $ | (0.23 | ) | | $ | 0.10 | | | $ | (0.14 | ) | | $ | 0.54 | |

| Diluted | | $ | (0.23 | ) | | $ | 0.10 | | | $ | (0.14 | ) | | $ | 0.46 | |

| Weighted average common shares outstanding | | | | | | | | | | | | |

| Basic | | | 28,626,136 | | | | 31,625,485 | | | | 29,630,665 | | | | 31,556,017 | |

| Diluted | | | 28,626,136 | | | | 31,743,162 | | | | 29,630,665 | | | | 36,959,274 | |

| | | | |

| Biote Corp. |

| Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited) |

| | | | |

| | | Six Months Ended June 30, | |

| | | 2026 | | | 2025 | |

| Operating Activities | | | | | | |

| Net income (loss) | | $ | (4,752 | ) | | $ | 19,764 | |

| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | | | | | | |

| Depreciation and amortization | | | 1,943 | | | | 1,767 | |

| Bad debt (recovery) expense | | | (771 | ) | | | 962 | |

| Amortization of debt issuance costs | | | 378 | | | | 412 | |

| Provision for (recovery of) obsolete inventory | | | (1,388 | ) | | | 1,100 | |

| Non-cash lease expense | | | 340 | | | | 268 | |

| Non-cash interest on share repurchase liability | | | — | | | | 1,986 | |

| Share-based compensation expense | | | 3,728 | | | | 4,313 | |

| Gain from change in fair value of earnout liabilities | | | (1,362 | ) | | | (8,856 | ) |

| Loss on extinguishment of debt | | | 648 | | | | — | |

| Deferred income taxes | | | 340 | | | | 1,285 | |

| Changes in operating assets and liabilities: | | | | | | |

| Accounts receivable | | | (171 | ) | | | (2,406 | ) |

| Inventory | | | 2,121 | | | | 1,613 | |

| Other assets | | | (1,116 | ) | | | (2,387 | ) |

| Accounts payable | | | (250 | ) | | | (1,950 | ) |

| Deferred revenue | | | (700 | ) | | | (60 | ) |

| Accrued expenses | | | 4,171 | | | | (3,910 | ) |

| Payments pursuant to TRA | | | (196 | ) | | | (93 | ) |

| Operating lease liabilities | | | (237 | ) | | | (255 | ) |

| Net cash provided by operating activities | | | 2,726 | | | | 13,553 | |

| Investing Activities | | | | | | |

| Purchases of property and equipment | | | (2,919 | ) | | | (3,439 | ) |

| Purchases of capitalized software | | | (873 | ) | | | (371 | ) |

| Net cash used in investing activities | | | (3,792 | ) | | | (3,810 | ) |

| Financing Activities | | | | | | |

| Repurchases of Class A common stock | | | (5,863 | ) | | | — | |

| Borrowings on revolving loans | | | 12,500 | | | | — | |

| Repayments on revolving loans | | | (17,500 | ) | | | — | |

| Principal repayments on term loan | | | (1,563 | ) | | | (3,125 | ) |

| Borrowings on term loan | | | 125,000 | | | | — | |

| Extinguishment of debt | | | (101,562 | ) | | | — | |

| Debt issuance costs | | | (3,431 | ) | | | — | |

| Payments on repurchase liability | | | (18,500 | ) | | | (25,081 | ) |

| Proceeds from exercise of stock options | | | — | | | | 226 | |

| Issuance of stock under purchase plan | | | 47 | | | | 72 | |

| Distributions | | | (1,021 | ) | | | (1,581 | ) |

| Net cash used in financing activities | | | (11,893 | ) | | | (29,489 | ) |

| Effect of exchange rate changes on cash and cash equivalents | | | 4 | | | | 5 | |

| Net decrease in cash and cash equivalents | | | (12,955 | ) | | | (19,741 | ) |

| Cash and cash equivalents at beginning of period | | | 24,123 | | | | 39,342 | |

| Cash and cash equivalents at end of period | | $ | 11,168 | | | $ | 19,601 | |

| Supplemental Disclosure of Cash Flow Information | | | | | | |

| Cash paid for interest | | $ | 2,774 | | | $ | 4,022 | |

| Cash paid for income taxes | | $ | 1,726 | | | $ | 2,508 | |

Biote Corp. Reconciliation of Adjusted EBITDA to Net Income (Loss) (Unaudited)

The following table presents a reconciliation of net income (loss) to Adjusted EBITDA, as well as the calculation of net income (loss) margin and Adjusted EBITDA margin, for each of the periods indicated.

| | | Three Months Ended | | | Six Months Ended | |

| | | June 30, | | | June 30, | |

| (in thousands) | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Net income (loss) | | $ | (7,428 | ) | | $ | 3,925 | | | $ | (4,752 | ) | | $ | 19,764 | |

| Interest expense, net(1) | | | 2,183 | | | | 2,852 | | | | 4,155 | | | | 5,757 | |

| Income tax expense | | | 296 | | | | 2,150 | | | | 958 | | | | 3,766 | |

| Depreciation and amortization(2) | | | 963 | | | | 910 | | | | 1,943 | | | | 1,767 | |

| Share-based compensation expense(3) | | | 1,970 | | | | 2,186 | | | | 3,728 | | | | 4,313 | |

| Litigation expenses-former owner(4) | | | — | | | | 82 | | | | 2 | | | | 232 | |

| Litigation-other(5) | | | 83 | | | | 427 | | | | 785 | | | | 892 | |

| Legal settlement and related expenses(6) | | | 5,065 | | | | (262 | ) | | | 5,590 | | | | (226 | ) |

| Restructuring-related expenses(7) | | | — | | | | 555 | | | | — | | | | 555 | |

| Other expenses(8) | | | 957 | | | | 517 | | | | 2,444 | | | | 852 | |

| Merger and acquisition expenses(9) | | | 37 | | | | — | | | | 147 | | | | 110 | |

| Loss on extinguishment of debt(10) | | | 648 | | | | — | | | | 648 | | | | — | |

| Loss (gain) from change in fair value of earnout liabilities | | | 787 | | | | 1,832 | | | | (1,362 | ) | | | (8,856 | ) |

| Adjusted EBITDA | | $ | 5,561 | | | $ | 15,174 | | | $ | 14,286 | | | $ | 28,926 | |

| Total revenue | | $ | 44,232 | | | $ | 48,863 | | | $ | 89,167 | | | $ | 97,855 | |

| Net income (loss) margin(11) | | | -16.8 | % | | | 8.0 | % | | | -5.3 | % | | | 20.2 | % |

| Adjusted EBITDA margin(12) | | | 12.6 | % | | | 31.1 | % | | | 16.0 | % | | | 29.6 | % |

| | | (1) | | Represents cash and non-cash interest on our debt obligations, commitment fees on the unused portion of our Revolving Loans, net of interest income earned on our money market account. For the three and six months ended June 30, 2025, interest expense, net included $0.9 million and $2.0 million of accreted interest related to the share repurchase liability. There was no accreted interest for the three and six months ended June 30, 2026. |

| | | | | |

| | | (2) | | Represents depreciation expense on property and equipment, amortization expense on capitalized software and amortization expense on purchased intangible assets. Depreciation expense of $0.2 million and $0.06 million for the three months ended June 30, 2026 and 2025, respectively, and $0.4 million and $0.07 million for the six months ended June 30, 2026 and 2025, respectively, was included in cost of products. |

| | | | | |

| | | (3) | | Represents employee compensation expense associated with equity-based stock awards. This includes expense associated with equity incentive instruments including phantom stock awards, stock options and restricted stock units. |

| | | | | |

| | | (4) | | Represents legal expenses to defend the Company against claims asserted by the Company’s former owner. |

| | | | | |

| | | (5) | | Represents litigation expenses other than those incurred in connection with claims asserted by the Company’s former owner that are not related to the Company’s ongoing business. |

| | | | | |

| | | (6) | | Represents legal expenses incurred in connection with litigation settlement gains or losses. |

| | | | | |

| | | (7) | | Represents restructuring costs incurred during the three and six months ended June 30, 2025 related to a workforce reduction primarily within our commercial organization. No such restructuring costs were incurred during the three and six months ended June 30, 2026. |

| | | | | |

| | | (8) | | Represents $0.8 million and $2.2 million incurred during the three and six months ended June 30, 2026, respectively, related to the January 2026 Voluntary Recall and primarily consists of a $0.6 million and $1.6 million, respectively, impact to cost of revenue and a $0.1 million and $0.7 million, respectively, impact to selling, general and administrative costs. For the three and six months ended June 30, 2025, this represents executive severance costs of $0.5 million and a realized foreign currency loss of less than $0.01 million and strategic consulting and legal expenses related to the CEO transition of $0.3 million for the six months ended June 30, 2025. |

| | | | | |

| | | (9) | | Represents legal fees totaling $0.04 million and $0.1 million incurred during the three and six months ended June 30, 2026 related to strategic opportunities to expand the business. For the six months ended June 30, 2025 this amount represents legal fees and professional fees totaling $0.1 million incurred to finalize the purchase price allocation of Asteria Health and for other strategic opportunities to expand the business. |

| | | | | |

| | | (10) | | Represents the remaining unamortized portion of the debt issuance costs related to the Credit Agreement written off upon executing the Amended Credit Agreement with Truist Bank. |

| | | | | |

| | | (11) | | Net income margin is defined as net income divided by total revenue. |

| | | | | |

| | | (12) | | Adjusted EBITDA margin is defined as adjusted EBITDA divided by total revenue. |

Contacts

Investor Relations: Eric Prouty AdvisIRy Partners [email protected]

Media: [email protected]

Prompts

Biote Corp. (ticker BTMD), listed in United States.

Company History

Date Change Detail
Mar 16, 2022 Renamed HAYMAKER ACQUISITION CORP. III → BIOTE CORP.

ETFs Holding Biote Corp.

ETF Weight in ETF Shares Market value As of
IVSS 0.03% 3,668 $ 6,932.52 Jun 30, 2026
DFAS 0.00% 224,120 $ 230.844K Nov 12, 2026